Immune to Cancer: The CRI Blog




Bladder Cancer Awareness Month: 2022 Immunotherapy Research Updates

CRI Clinical Team Leader Dr. Lawrence Fong of the University of California, San Francisco, contributed to two studies on urotherial cancer presented at the ASCO Genitourinary Cancers Symposium in February 2022. One study assessed biomarkers predictive of response to treatment with the antibody-drug conjugate enfortumab vedotin. The other assessed the impact of primary tumor location on efficacy and safety of the checkpoint inhibitor pembrolizumab in the KEYNOTE-052 and KEYNOTE-045 trials. These studies demonstrate the precision and consideration given to ensure patients receive the best treatment possible for bladder cancer.  

This May, for Bladder Cancer Awareness Month, discover new research, new treatments, and progress for a future immune to bladder cancers.

Bladder Cancer Treatment Update

At the CRI Virtual Immunotherapy Patient Summit last October, Dr. Arjun Balar of NYU Langone Health discussed how oncologists predict patient response to immunotherapies, common mutations, and other topics.

Bladder Cancer Patient Story

Given only six months left to live, Ron enrolled in a clinical trial combining the immunotherapies nivolumab (Opdivo®) and ipilimumab (Yervoy®). 


Bladder Cancer Scientist Spotlight

CRI Clinical Accelerator Investigator Dr. Nina Bhardwaj is co-chair of a study examining combinations of two checkpoint immunotherapies, plus an immune-stimulating adjuvant, in a wide variety of patients.

Learn more about the clinical trial

Immunotherapy for Bladder Cancer

New immunotherapies have significantly reduced the risk of recurrence for bladder cancer while also increasing the percentage of patients who see a complete response post-surgery. 

READ Bladder Cancer UPDATE

Find a Bladder Cancer Clinical Trial

Help speed the development of potentially lifesaving drugs. Discover trials for which you or a loved one may be eligible with the CRI Immunotherapy Clinical Trial Finder.

FIND A Cancer Clinical TRIAL

Support Bladder Cancer Research

CRI Lloyd J. Old STAR Dr. Alexander Marson of UCSF recently headed a study published in Nature that shed light on how obesity can change the immune system. Consequently, his efforts helped define how clinicians might be able to better treat allergies, asthma, and even cancer in this population. This Bladder Cancer Awareness Month, support lifesaving cancer immunotherapy research.

DONATE to bladder cancer research

Read more:

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.